• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV-1 包膜糖蛋白中的自然变异和细胞进入抑制剂的开发。

Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors.

机构信息

Department of Biology, The Johns Hopkins University, Baltimore, Maryland 21218, USA.

出版信息

Biochemistry. 2010 Mar 23;49(11):2359-67. doi: 10.1021/bi1000933.

DOI:10.1021/bi1000933
PMID:20166763
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2840190/
Abstract

Naturally occurring genetic variability across HIV-1 subtypes causes amino acid polymorphisms in encoded HIV-1 proteins including the envelope glycoproteins associated with viral entry. The effects of amino acid polymorphisms on the mechanism of HIV-1 entry into cells, a process initiated by the binding of the viral envelope glycoprotein gp120 to the cellular CD4 receptor, are largely unknown. In this study, we demonstrate that amino acid polymorphisms affect the structural stability and domain cooperativity of gp120 and that those differences are reflected in the binding mechanism of the viral envelope glycoprotein to the cell surface receptor and coreceptor. Moreover, subtype differences also affect the binding behavior of experimental HIV cell entry inhibitors. While gp120-A has a slightly lower denaturation temperature than gp120-B, the most notable stability difference is that for gp120-B the van't Hoff to calorimetric enthalpy ratio (DeltaH(vH)/DeltaH) is 0.95 whereas for gp120-A is 0.6, indicative of more cooperative domain/domain interactions in gp120-B, as this protein more closely approaches a two-state transition. Isothermal titration calorimetry demonstrates that CD4 and 17b (a surrogate antibody for the chemokine coreceptor) exhibit 7- and 3-fold weaker binding affinities for gp120-A. The binding of these proteins as well as that of the experimental entry inhibitor NBD-556 induces smaller conformational changes in gp120-A as evidenced by significantly smaller binding enthalpies and binding entropies. Together, these results describe the effects of gp120 polymorphisms on binding to host cell receptors and emphasize that guidelines for developing future entry inhibitors must recognize and deal with genomic differences between HIV strains.

摘要

HIV-1 各亚型之间天然存在的遗传变异性导致编码 HIV-1 蛋白的氨基酸发生多态性,其中包括与病毒进入相关的包膜糖蛋白。氨基酸多态性对 HIV-1 进入细胞的机制的影响尚不清楚,该过程是由病毒包膜糖蛋白 gp120 与细胞表面 CD4 受体结合引发的。在这项研究中,我们证明了氨基酸多态性会影响 gp120 的结构稳定性和结构域协同性,这些差异反映在病毒包膜糖蛋白与细胞表面受体和共受体的结合机制中。此外,亚型差异也会影响实验性 HIV 细胞进入抑制剂的结合行为。虽然 gp120-A 的变性温度略低于 gp120-B,但最显著的稳定性差异是,对于 gp120-B,van't Hoff 到量热焓比(DeltaH(vH)/DeltaH)为 0.95,而对于 gp120-A 为 0.6,这表明 gp120-B 中结构域/结构域相互作用更具协同性,因为该蛋白更接近二态转变。等温滴定量热法表明,CD4 和 17b(趋化因子共受体的替代抗体)与 gp120-A 的结合亲和力分别弱 7 倍和 3 倍。这些蛋白的结合以及实验性进入抑制剂 NBD-556 的结合会引起 gp120-A 发生较小的构象变化,这可以从较小的结合焓和结合熵得到证明。综上所述,这些结果描述了 gp120 多态性对与宿主细胞受体结合的影响,并强调了开发未来进入抑制剂的指南必须认识到并处理 HIV 株之间的基因组差异。

相似文献

1
Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors.HIV-1 包膜糖蛋白中的自然变异和细胞进入抑制剂的开发。
Biochemistry. 2010 Mar 23;49(11):2359-67. doi: 10.1021/bi1000933.
2
Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.一种低分子量CD4模拟物与HIV-1 gp120结合的热力学
Biochemistry. 2006 Sep 12;45(36):10973-80. doi: 10.1021/bi061193r.
3
Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators.改变的 Env 构象动力学作为对肽-三唑 HIV-1 失活剂产生耐药性的机制。
Retrovirology. 2021 Oct 9;18(1):31. doi: 10.1186/s12977-021-00575-z.
4
Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.CD4模拟化合物对原代人免疫缺陷病毒包膜糖蛋白三聚体的激活与失活作用
J Virol. 2017 Jan 18;91(3). doi: 10.1128/JVI.01880-16. Print 2017 Feb 1.
5
Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4.抗体17b在共受体位点的结合减弱了包膜糖蛋白gp120与CD4相互作用的动力学。
Biochemistry. 2001 Feb 13;40(6):1662-70. doi: 10.1021/bi001397m.
6
Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.基于结构的HIV-1进入的CD4模拟小分子抑制剂的设计、合成及验证:从病毒进入激动剂到拮抗剂的转变
Acc Chem Res. 2014 Apr 15;47(4):1228-37. doi: 10.1021/ar4002735. Epub 2014 Feb 6.
7
Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.鉴定对 CD4 模拟化合物具有耐药性的人类免疫缺陷病毒(HIV-1)包膜糖蛋白变异体。
J Virol. 2022 Sep 14;96(17):e0063622. doi: 10.1128/jvi.00636-22. Epub 2022 Aug 18.
8
Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.HIV-1 gp120 的构象和结构特征,解释了交叉反应性中和抗体 m18 产生双重受体拮抗作用的原因。
Biochemistry. 2011 Apr 12;50(14):2756-68. doi: 10.1021/bi101160r. Epub 2011 Mar 18.
9
Peptide ligands selected with CD4-induced epitopes on native dualtropic HIV-1 envelope proteins mimic extracellular coreceptor domains and bind to HIV-1 gp120 independently of coreceptor usage.用 CD4 诱导的天然双重嗜性 HIV-1 包膜蛋白上的表位选择的肽配体模拟细胞外共受体结构域,并独立于共受体使用与 HIV-1 gp120 结合。
J Virol. 2010 Oct;84(19):10131-8. doi: 10.1128/JVI.00165-10. Epub 2010 Jul 21.
10
HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike.HIV-1通过稳定包膜糖蛋白刺突逃避一种肽类锚定抑制剂
J Virol. 2016 Nov 14;90(23):10587-10599. doi: 10.1128/JVI.01616-16. Print 2016 Dec 1.

引用本文的文献

1
Binding Thermodynamics to Intrinsically Disordered Protein Domains.结合热力学性质于无序蛋白质结构域。
Methods Mol Biol. 2020;2141:449-462. doi: 10.1007/978-1-0716-0524-0_22.
2
Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.在一项评估 HIV-1 附着抑制剂前药福替司韦的 2b 期、随机、对照临床试验中,病毒耐药性持续 48 周。
J Acquir Immune Defic Syndr. 2018 Mar 1;77(3):299-307. doi: 10.1097/QAI.0000000000001602.
3
Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen.丙型肝炎病毒E2抗原上一个主要保守抗体靶点的结构灵活性。
Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12768-12773. doi: 10.1073/pnas.1609780113. Epub 2016 Oct 24.
4
Three easy pieces.三个简单部分。
Biochim Biophys Acta. 2016 May;1860(5):975-980. doi: 10.1016/j.bbagen.2015.12.003. Epub 2015 Dec 9.
5
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.一种下一代裂解可溶性 HIV-1 包膜三聚体 BG505 SOSIP.664 gp140,表达多种广谱中和但非非中和抗体的表位。
PLoS Pathog. 2013 Sep;9(9):e1003618. doi: 10.1371/journal.ppat.1003618. Epub 2013 Sep 19.
6
Ligand binding analysis and screening by chemical denaturation shift.配体结合分析和化学变复性筛选。
Anal Biochem. 2013 Dec 1;443(1):52-7. doi: 10.1016/j.ab.2013.08.015. Epub 2013 Aug 29.
7
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.HIV-1 三聚体被广谱中和抗体 PG9 不对称识别。
Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4351-6. doi: 10.1073/pnas.1217537110. Epub 2013 Feb 20.
8
Optimization of CD4/gp120 inhibitors by thermodynamic-guided alanine-scanning mutagenesis.基于热力学指导的丙氨酸扫描突变优化 CD4/gp120 抑制剂。
Chem Biol Drug Des. 2013 Jan;81(1):72-8. doi: 10.1111/cbdd.12075.
9
A flavonoid, luteolin, cripples HIV-1 by abrogation of tat function.一种黄酮类化合物,木樨草素,通过废除 tat 功能使 HIV-1 瘫痪。
PLoS One. 2011;6(11):e27915. doi: 10.1371/journal.pone.0027915. Epub 2011 Nov 30.
10
Thermodynamics-based drug design: strategies for inhibiting protein-protein interactions.基于热力学的药物设计:抑制蛋白-蛋白相互作用的策略。
Future Med Chem. 2011 Jul;3(9):1129-37. doi: 10.4155/fmc.11.81.

本文引用的文献

1
Binding of small-molecule ligands to proteins: "what you see" is not always "what you get".小分子配体与蛋白质的结合:“所见”未必“所得”。
Structure. 2009 Apr 15;17(4):489-98. doi: 10.1016/j.str.2009.02.010.
2
Binding thermodynamics of the N-terminal peptide of the CCR5 coreceptor to HIV-1 envelope glycoprotein gp120.趋化因子受体CCR5辅助受体N端肽与HIV-1包膜糖蛋白gp120的结合热力学
Biochemistry. 2009 Feb 3;48(4):779-85. doi: 10.1021/bi8021476.
3
Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120.小分子CD4模拟物与HIV-1 gp120上一个高度保守的口袋相互作用。
Structure. 2008 Nov 12;16(11):1689-701. doi: 10.1016/j.str.2008.09.005.
4
Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.临床使用的HIV-1蛋白酶抑制剂对HIV-2蛋白酶的抑制作用。
Chem Biol Drug Des. 2008 Apr;71(4):298-305. doi: 10.1111/j.1747-0285.2008.00647.x. Epub 2008 Feb 28.
5
Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection.1型人类免疫缺陷病毒(HIV-1)亚型对乌干达拉凯地区初发HIV-1感染人群疾病进展的影响。
J Infect Dis. 2008 Mar 1;197(5):707-13. doi: 10.1086/527416.
6
HIV-1 subtype as a determinant of disease progression.HIV-1 亚型作为疾病进展的一个决定因素。
J Infect Dis. 2008 Mar 1;197(5):638-9. doi: 10.1086/527417.
7
Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.一种低分子量CD4模拟物与HIV-1 gp120结合的热力学
Biochemistry. 2006 Sep 12;45(36):10973-80. doi: 10.1021/bi061193r.
8
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.针对抗逆转录病毒药物耐药性替代的计算得出的遗传屏障,在不同的HIV-1亚型中大体相似。
J Acquir Immune Defic Syndr. 2006 Mar;41(3):352-60. doi: 10.1097/01.qai.0000209899.05126.e4.
9
Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.鉴定N-苯基-N'-(2,2,6,6-四甲基哌啶-4-基)草酰胺为一类新型的HIV-1进入抑制剂,其可阻止gp120与CD4结合。
Virology. 2005 Sep 1;339(2):213-25. doi: 10.1016/j.virol.2005.06.008.
10
Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness.人类免疫缺陷病毒1型亚型对一线抗逆转录病毒治疗效果的影响。
Antivir Ther. 2005;10(2):247-54.